Agilent, Seoul National University To Collaborate On Biomarker Research

Agilent and Seoul National University Hospital are set to collaborate on the development of biomarkers and drugs.

AsianScientist (Oct. 18, 2013) – Agilent Technologies and Seoul National University Hospital are set to collaborate on the development of various biomarkers and drugs, including narcotics, immune-suppressants and biomarkers.

“There are gaps in the medical industry that hamper the quality of care we can provide to patients,” said professor Byung-Hee Oh, president and CEO of Seoul National University Hospital.

“One area we want to address is the development of biomarkers for early detection and effective monitoring of a range of diseases,” he said.

Professor Oh said that working together with Agilent Technologies could help stretch the horizons of medical research and improve the lives of people in Korea and around the world.

Under the agreement, the hospital’s Department of Laboratory Medicine will use the Agilent 6460 Triple Quadrupole LC/MS (liquid chromatography-mass spectrometry) system as well as Agilent’s support services and application expertise.

“Through this collaboration, we hope to establish a more effective and varied verification system for the medical and life sciences industries,” said Agilent’s Rod Minett, general manager of Life Sciences in South Korea and the South Asia-Pacific region.

——

Source: Agilent Technologies.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist